> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nektar NDA for Pain Drug with Reduced Euphoria
- URL: https://www.fdaweb.com/nektar-nda-for-pain-drug-with-reduced-euphoria/
- Published: 2018-05-31T12:00:00.000Z
- Updated: 2026-09-15T00:09:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141576

Nektar Therapeutics has submitted an NDA for NKTR-181, an analgesic opioid molecule that the company says exhibits a reduced incidence of specific side effects, such as euphoria, through the targeted alteration of brain-entry kinetics. The submission is supported by clinical data from 15 studies in 2,234 subjects, pharmacokinetic/pharmacodynamic studies in over 450 subjects, and two human abuse-potential studies evaluating both therapeutic and supratherapeutic doses of NKTR-181 versus an oxycodone control in recreational drug users.

The new molecular entity is described by Nektar as a selective full mu-opioid agonist designed to provide potent pain relief. It is designed to have “low permeability across the blood-brain barrier in order to slow its rate of entry into the brain and attenuate the dopamine release that underlies euphoria,” it says. “In addition, NKTR-181 has a 14-hour elimination half-life to enable twice-daily dosing for pain control.”